


INFORMATION DISCLOSURE CITATION IN AN APPLICATION 	ATTY. DOCKET NO. 066821-233	SERIAL NO. 10/648,813
	APPLICANT Ruoslahti, et al.	
	FILING DATE August 25, 2003	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
---------------------	----------	---	--------------------------------	---	---

4	1.	US	5,320,970	06-14-1994	Eyre et al.	
	2.	US	5,541,295	07-30-1996	Barrach et al.	
	3.	US	5,763,272	06-09-1998	Naser et al.	
	4.	US	6,030,792	02-29-2000	Otterness et al.	
	5.	US	6,132,976	10-17-2000	Poole et al.	
	6.	US	2003/0113331 A1	06-19-2003	Brooks et al.	
	7.	US	2004/0091482 A9	05-13-2004	Watkins et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number - Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
---------------------	----------	---	--------------------------------	---	---	-----------------------

U H	8.	EP 0 510 949 A2	10-28-1992	Pouletty. P.		
	9.	EP 0 921 395 A2	12-11-1998	Downs et al.		
	10.	WO 94/14070 A1	06-23-1994	Poole et al.		
	11.	WO 95/04282 A1	02-09-1995	Naser et al.		
	12.	WO 97/44059 A2	11-27-1997	Poole et al.		
	13.	WO 98/35235 A1	08-13-1998	Hollander et al.		
	W	14.	WO 99/06840 A1	02-11-1999	Krane et al.	
15.		WO 00/40597	07-13-2000	Brooks et al.		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
---------------------	----------	---

4	16.	Bellon, "Quantification and specific detection of collagenous proteins using an enzyme-linked immunosorbent assay and an immunoblotting for cyanogen bromide peptides," <u>Analytical Biochemistry</u> 150, 188-202 (1985).
	17.	Borza et al., "The Goodpasture Autoantigen," <u>J. Biol. Chem.</u> 275(8):6030-6037 (2000).
	18.	David et al., "Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen," <u>J. Biol. Chem.</u> 276(9):6370-6377 (2001).


EXAMINER



DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066821-233	SERIAL NO. 10/648,813
	APPLICANT Ruoslahti, et al.	
	FILING DATE August 25, 2003	GROUP 1642

	19.	Kalluri et al., "Specificity of circulating and tissue-bound autoantibodies in Goodpasture Syndrome," <u>Pro. Assoc. Am. Physicians</u> 108(2)134-139 (1996).	
	20.	Nakanishi et al., "Immunohistochemical study of α 1-5 chains of type IV collagen in hereditary nephritis," <u>Kid. Inter.</u> 46:1413-1421 (1994).	
	21.	Timpl, "Antibodies to collagens and procollagens," <u>Methods in Enzymology</u> 82:472-498 (1982).	
	22.	Wheatcroft et al., "Evidence of in situ stability of the type IV collagen triple helix in human inflammatory bowel disease using a denaturation of specific epitope antibody," <u>Matrix Biology</u> 18:361-372 (1999).	
	23.	Wick et al., "Characterization of antibodies to basement membrane (type iv) collagen in immunohistological studies," <u>Immunobiol.</u> 156:372-381 (1979).	
	24.	Xu et al., "Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization," <u>Hybridoma</u> , 19(5): 375-385 (2000).	
	25.	Xu et al., "Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo," <u>J. Cell Biol.</u> , 154(5):1069-1079 (2001).	
	26.	Yoshioka et al., "Type IV collagen α 5 chain," <u>Am. J. Path.</u> 144(5)986-996 (1994).	

EXAMINER 	DATE CONSIDERED 
---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached